Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
about
DangER: protein ovERload. Targeting protein degradation to treat myelomaIncorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like SitesSelective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic CysteineAssessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probesDiscovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicityMolecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Identification of a molecular target of a novel fungal metabolite, pyrrolizilactone, by phenotypic profiling systems.Multicolor monitoring of the proteasome's catalytic signature.Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.Subunit specific inhibitors of proteasomes and their potential for immunomodulationA strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.Flumazenil decreases surface expression of α4β2δ GABAA receptors by increasing the rate of receptor internalizationNelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).Activity-based imaging probes of the proteasome.A FRET-based approach for identification of proteasome catalytic subunit composition.Proteasome inhibitors: an expanding army attacking a unique target.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Synthesis and pharmacology of proteasome inhibitors.Peptide-based proteasome inhibitors in anticancer drug design.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Proteasome as a Molecular Target of Microcystin-LRActivity-based probes for the multicatalytic proteasome.Acute cigarette smoke exposure impairs proteasome function in the lung.Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.Synthesis of C3/C1-Substituted Tetrahydroisoquinolines.Immunoproteasome inhibition and bioactivity of thiasyrbactins.Titania-Coated Gold Nano-Bipyramids for Blocking Autophagy Flux and Sensitizing Cancer Cells to Proteasome Inhibitor-Induced Death.Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S Proteasome
P2860
Q26825417-9C7AE51C-E462-4625-ADB5-92B97DD40E3FQ27675903-4F7C9335-8029-4674-A751-7A61EF183EE8Q27702605-622789D6-6F90-4B35-AF3F-0DE8E8F9819FQ34061291-04434BFF-BAF8-4A12-8410-53F53D633338Q34079904-1AC6762C-5BB5-4BC8-8F0F-B0C3E232BE61Q34473136-CC902CB8-29BA-4942-94F5-541BF2015488Q34608271-DFB0819A-E010-402A-BE5B-EBEFFEFFDA11Q35027521-A6F07D7C-AF42-4F9D-B837-D255A35BA1FEQ35121111-21C557FF-C9A7-497C-891C-CE077AF1B620Q35555565-E04837B2-C344-43DF-8518-D61A2F5A9B6AQ35559055-A7AFA804-F3E1-496A-A553-B9E602C14D5EQ35764713-2678565A-32F3-4E05-AB68-F95D92985F38Q35889653-0E1E9552-1C1C-435D-AEA7-7B9B085FB2D7Q36042649-AC764549-AD6D-448F-BB4C-06B482D9582AQ36290627-AFA2A545-A49B-47A4-A939-29CB4AA4BDDAQ36418506-5889C2B3-4729-4D61-935B-48CC98A06732Q36736534-49F9ADD8-6FA1-4AA6-BFB5-4AA3B13CACADQ36750467-2ADE7341-3C6A-49A7-9BAC-1E3DAB967EB6Q37136304-B63CF91B-6B01-49EB-B8E2-4F61CFCA07C6Q37502160-7EE83501-B1AE-456D-80A0-F5A5E1F224BAQ37979388-264E6C59-DA4B-4846-8210-27EFC0BD9F1FQ38019864-FFA7A5BE-34DE-4CC7-B609-7819DA6D9F71Q38092777-5EB6D9DB-EF1C-4426-9B30-56505E9C4BF8Q38192572-EDB1FD58-565E-49E9-8DEC-43BC023D13AFQ38246060-DE8821AF-1264-4F9D-A543-8C0E8DA7A067Q38862262-1FBE6050-381B-477E-975E-957F0D99977AQ39096761-8AE45391-DFF7-43C5-8B72-4F2B65515206Q39282499-6AFE2D39-5A39-418E-833D-59BFA6040D87Q41531584-49EC4EF0-4051-43CB-B657-3257E3658930Q41607725-96431F0B-BDE9-4B62-B6AA-466F0AC2AC48Q47102326-AFCEB10E-2648-417B-8B67-FD02032B5F49Q47987649-D5A0E857-69E6-4A32-A2ED-E22B00084BE0Q50944497-1056923E-5A26-4CE0-B2F6-CBD3FC82974FQ52406227-5D54BAFC-F36E-48EF-AE2E-18419A538C51Q55344771-EF368D3F-F9C1-447D-A18A-ABBAA28C05B5Q57114402-594E7594-A563-4F1D-8B2F-26F8A8547A2B
P2860
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Specific cell-permeable inhibi ...... to bortezomib and carfilzomib.
@en
Specific cell-permeable inhibi ...... to bortezomib and carfilzomib.
@nl
type
label
Specific cell-permeable inhibi ...... to bortezomib and carfilzomib.
@en
Specific cell-permeable inhibi ...... to bortezomib and carfilzomib.
@nl
prefLabel
Specific cell-permeable inhibi ...... to bortezomib and carfilzomib.
@en
Specific cell-permeable inhibi ...... to bortezomib and carfilzomib.
@nl
P2093
P2860
P50
P1476
Specific cell-permeable inhibi ...... to bortezomib and carfilzomib.
@en
P2093
Alexandre A Pletnev
Alexei F Kisselev
Anne C Mirabella
Dmitri V Filippov
Matthew Britton
Tamer B Shabaneh
P2860
P304
P356
10.1016/J.CHEMBIOL.2011.02.015
P577
2011-05-01T00:00:00Z